Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anniina Virtanen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Archives of Occupational and Environmental Health|September 26, 2019
Relationships between recovery experiences and well-being among younger and older teachersAnniina Virtanen, Jessica De Bloom, Ulla Kinnunen
SLAS Discovery : Advancing Life Sciences R & D|May 6, 2023
Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screeningAngelika Pölläniemi, Anniina Virtanen, Olli Silvennoinen, et al.
Stress and Health : Journal of the International Society for the Investigation of Stress|March 5, 2021
Drammatic breaks: Break recovery experiences as mediators between job demands and affect in the afternoon and eveningAnniina Virtanen, Michelle Van Laethem, Jessica de Bloom, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2023
Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro ProfilingAnniina Virtanen, Maaria Palmroth, Sanna Liukkonen, et al.
Advances in Biological Regulation|January 4, 2025
Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug targetAnniina Virtanen, Vivian Kettunen, Kirsikka Musta, et al.
Nature Reviews. Rheumatology|September 9, 2024
JAK inhibitor selectivity: new opportunities, better drugs?Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Journal of Medicinal Chemistry|June 6, 2024
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug SelectivityYa Miao, Anniina Virtanen, Jakub Zmajkovic, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
<i>IRF2BP2</i> Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and LymphopeniaMaaria Palmroth, Hanna Viskari, Mikko R J Seppänen, et al.
Frontiers in Immunology|October 11, 2021
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis <i>In Vivo</i> and Baseline Signaling Profile Associates With Treatment ResponseMaaria Palmroth, Krista Kuuliala, Ritva Peltomaa, et al.
Clinical and Experimental Immunology|September 20, 2022
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment responseAtte Valli, Krista Kuuliala, Anniina Virtanen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Archives of Occupational and Environmental Health|September 26, 2019
Relationships between recovery experiences and well-being among younger and older teachersAnniina Virtanen, Jessica De Bloom, Ulla Kinnunen
SLAS Discovery : Advancing Life Sciences R & D|May 6, 2023
Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screeningAngelika Pölläniemi, Anniina Virtanen, Olli Silvennoinen, et al.
Stress and Health : Journal of the International Society for the Investigation of Stress|March 5, 2021
Drammatic breaks: Break recovery experiences as mediators between job demands and affect in the afternoon and eveningAnniina Virtanen, Michelle Van Laethem, Jessica de Bloom, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2023
Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro ProfilingAnniina Virtanen, Maaria Palmroth, Sanna Liukkonen, et al.
Advances in Biological Regulation|January 4, 2025
Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug targetAnniina Virtanen, Vivian Kettunen, Kirsikka Musta, et al.
Nature Reviews. Rheumatology|September 9, 2024
JAK inhibitor selectivity: new opportunities, better drugs?Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Journal of Medicinal Chemistry|June 6, 2024
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug SelectivityYa Miao, Anniina Virtanen, Jakub Zmajkovic, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
<i>IRF2BP2</i> Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and LymphopeniaMaaria Palmroth, Hanna Viskari, Mikko R J Seppänen, et al.
Frontiers in Immunology|October 11, 2021
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis <i>In Vivo</i> and Baseline Signaling Profile Associates With Treatment ResponseMaaria Palmroth, Krista Kuuliala, Ritva Peltomaa, et al.
Clinical and Experimental Immunology|September 20, 2022
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment responseAtte Valli, Krista Kuuliala, Anniina Virtanen, et al.
Pageof 1